arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Verrica Pharmaceuticals Inc.

VRCA

$5.16 ▼ -0.18 (-3.46%) at close

10 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Moderately Bearish

auto_awesome

Analytical Summary

Verrica Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $55.0M

Dividend Yield —

Revenue Growth 370.2% ↗

Op. Margin -34.2%

ROIC -38.9% ↗

FCF / Share $-1.65 ↗

Trailing P/E —

Price / Book 3.6x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$35.58M

↑ +370.2% —

Net Income Profit after all expenses

$-17.89M

↑ +76.6% —

Operating Margin Operating profit as % of sales

-34.2%

↑ +85.5% 7th

FCF / Share Free cash flow per share

$-1.65

↑ +85.9% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	370.2% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4528%)	47.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+496%)	-43.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-641%)	-24.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-409%)	—	—	—	—	—	—
EPS Growth YoY (%)	88.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-105.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	44.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	76.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-14.3% Weak ↑ Weak Improving Year-over-year change in net income	-173.6% Weak ↓ Weak Declining Year-over-year change in net income	30.2% Excellent ↑ Excellent Improving Year-over-year change in net income	17.8% Good ↑ Good Improving Year-over-year change in net income	-51.4% Weak ↑ Weak Improving Year-over-year change in net income	-36.6% Weak Weak Year-over-year change in net income	-363.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	85.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-37.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	-54.8% Weak Weak Year-over-year change in free cash flow	47.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	57.9% Excellent Excellent Compound annual revenue growth over 3 years	-14.3% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	-34.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-328%)	—	—	-235.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1672%)	-257.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1817%)	—	—	—	—	—
Profit Margin (%) (%)	-50.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-519%)	—	—	-271.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2359%)	-292.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2536%)	—	—	—	—	—
FCF Margin (%) (%)	-49.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-209.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-237.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-38.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-246.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-82.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-74.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-96.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	50.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-121.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-80.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-38.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-54.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-49.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-72.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-582%)	—	—	-61.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-508%)	-107.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-817%)	-129.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-963%)	-43.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-389%)	-23.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-254%)	63.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+322%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	0.00x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	-3.14x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-624%)	2.17x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+262%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	1.28x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+113%)	1.07x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+78%)	—	—	—	—
Interest Coverage (x)	-2.36x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.12x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-16.60x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-9.80x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-7.20x Weak Weak Operating income divided by interest expense Optimal: > 5x	-13.24x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-4457.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-30.15M	$-15.35M	$-26.67M	$-34.27M	$25.94M	$24.63M	$-9.24M	$-10.27M	$-8.66M	$-527.00K
Debt / EBITDA (x)	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.47x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.66x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.36x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.88x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$3.34	$1.46	$1.13	$2.64	$4.44	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.68	$-14.80	$-14.80	$-7.20	$-13.00	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.65	$-11.77	$-8.59	$-5.55	$-10.53	—	—	—	—	—
Book Value per Share (USD)	$1.44	$-1.07	$4.66	$9.74	$11.85	$12.97	$25.21	$34.79	$-19.03	—
Tangible Book Value per Share (USD)	$1.44	$-1.07	$4.66	$9.74	$11.85	$12.97	$25.21	$34.79	$-19.03	—
Basic Weighted Avg Shares (shares)	10.65M	5.18M	4.53M	3.42M	2.70M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$26.10M	$22.17M	$60.51M	$35.66M	$28.27M	$28.18M	$61.63M	$88.67M	$8.47M	—
LT Debt (USD)	$0.00	$30.98M	$42.87M	$0.00	—	—	—	—	—	—
Total Equity (USD)	$24.74M	$-9.86M	$19.76M	$40.03M	$32.60M	$32.99M	$65.02M	$89.43M	$-7.04M	$-2.66M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$35.58M	$7.57M	$5.12M	$9.03M	$12.00M	—	—	—	—	—
Depreciation Expense (USD)	$133.00K	$342.00K	$530.00K	$454.00K	$244.00K	$43.00K	$64.20K	$20.30K	—	—
Net Income, GAAP (USD)	$-17.89M	$-76.58M	$-67.00M	$-24.49M	$-35.08M	$-42.69M	$-28.21M	$-20.65M	$-4.46M	—
Operating Cash Flow (USD)	$-17.63M	$-60.93M	$-38.58M	$-18.65M	$-27.58M	$-30.21M	$-27.41M	$-17.87M	$-4.58M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

Verrica Pharmaceuticals Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VRCA with peers